Published in Blood Weekly, March 23rd, 2006
The issued claims encompass the use of Alexion's lead drug candidate, eculizumab, to inhibit complement activation in humans. Complement inhibition is the key mechanism of action for eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), which Alexion is currently developing under the brand name Soliris.
"The issuance of this Japanese patent represents a key...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.